Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

Zesiewicz, Theresa; Evatt, Marian L.; Vaughan, Camille P.; Jahan, Israt; Singer, Carlos; Ordorica, Raul; Salemi, Jason L.; Shaw, Jessica; Sullivan, Kelly L.

doi:10.1016/j.parkreldis.2015.02.025

Cited by 61 publications

(47 citation statements)

References 21 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 1 study was evaluated for the treatment of urinary dysfunction in PD, and 1 trial not meeting inclusion criteria was excluded . See Table for recommendations.…”

Section: Results and Conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

et al. 2019

View full text Add to dashboard Cite

Objective To update evidence‐based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). Background The International Parkinson and Movement Disorder Society Evidence‐Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016. Methods Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported. Results A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non‐dementia‐level cognitive impairment. Conclusions The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

show abstract

“…A total of 1 study was evaluated for the treatment of urinary dysfunction in PD, and 1 trial not meeting inclusion criteria was excluded . See Table for recommendations.…”

Section: Results and Conclusionmentioning

confidence: 99%

“…Solifenacin for the treatment of overactive bladder was evaluated in a high‐quality, negative study . Because there were some significant benefits in the active arm, there is “ insufficient evidence” to make a conclusion on efficacy.…”

Section: Results and Conclusionmentioning

confidence: 99%

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Standing blood pressures should be measured and it may be necessary to prioritise symptomatic orthostatic hypotension over sitting or supine hypertension. Urinary dysfunctions, including urgency and nocturia, are among the most prevalent non‐motor symptoms in PD but evidence concerning effective therapies is limited. In one randomised controlled trial, solifenacin reduced incontinence but not the frequency of micturition compared with placebo .…”

Section: Non‐motor Symptomsmentioning

confidence: 99%

“…Urinary dysfunctions, including urgency and nocturia, are among the most prevalent non‐motor symptoms in PD but evidence concerning effective therapies is limited. In one randomised controlled trial, solifenacin reduced incontinence but not the frequency of micturition compared with placebo . Constipation is also very common, with limited evidence supporting the use of the osmotic laxative macrogol and, more recently, lubiprostone.…”

Section: Non‐motor Symptomsmentioning

confidence: 99%

Updates and advances in the treatment of Parkinson disease

Hayes

Fung

Kimber

et al. 2019

Medical Journal of Australia

View full text Add to dashboard Cite

Summary Parkinson disease (PD) is a complex neurodegenerative disorder that can present heterogeneously with a combination of motor and non‐motor symptoms. α‐synuclein, a neuronal protein, can undergo aberrant conformational change resulting in the intra‐neuronal accumulation of toxic oligomers that form Lewy bodies, the pathological hallmark of PD. There is evidence that pathological α‐synuclein exhibits prion‐like behaviour in its mode of transmission through the nervous system. The choice of initial dopaminergic treatments should be individually tailored but long term outcomes appear to be equivalent. There is level A evidence supporting the benefit of three different device‐assisted therapies in treating troublesome motor fluctuations and dyskinesias. Stem cell transplantation as currently being trialled is predominantly a symptomatic therapy targeting only limited regions of the brain affected by PD, and will need to be proven to be not only as effective but as safe as currently available device‐assisted therapies. New modes of treatment including active immunisation against oligomeric α‐synuclein and drugs that alter cellular metabolism show some promise. The inability to effectively treat a range of non‐motor, non‐dopaminergic symptoms remains a major therapeutic challenge.

show abstract

“…For storage symptoms, antimuscarinergics are commonly used. To avoid cognitive adverse effects, those that cannot penetrate the blood-brain barrier and spare M1 receptor should be chosen, such as solifenacin and darifenacin [114,122]. Mirabegron, a b3 adrenergic receptor is promising and a clinical trial in PD is ongoing [123].…”

Section: The Influence Of Dopaminergic Treatments and Dbsmentioning

confidence: 99%

Recognition and treatment of autonomic disturbances in Parkinson’s disease

Reichmann

Ziemssen

2015

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Symptoms of dysautonomia are common in Parkinson's disease (PD), and almost all the functional autonomic subsystems can be involved in PD. However, they are still under-recognized in everyday clinical practice. Autonomic dysfunction can be observed in the early stages of PD, affect a substantial proportion of patients, impact quality of life and can also help in differential diagnosis. This review aims to provide an overview of the pathophysiology, clinical manifestations, relevant examination and treatment of cardiovascular, gastrointestinal, urogenital, thermoregulatory and pupil autonomic dysfunctions in Parkinson's disease.

show abstract

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

Cited by 61 publications

References 21 publications

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

Updates and advances in the treatment of Parkinson disease

Recognition and treatment of autonomic disturbances in Parkinson’s disease

Contact Info

Product

Resources

About